Funding for this research was provided by:
Text and Data Mining valid from 2019-03-04
Received: 14 January 2019
Accepted: 28 February 2019
First Online: 4 March 2019
Compliance with ethical standards
: GF, MM, MWM, EK, GJ, NG, SR, AB, IS, VB, SKG, CK, HR, PGS, RDK and UB have received research funding and expense allowance for study conduct from Oncoscience GmbH. GF and UB have received support from Oncoscience GmbH for meeting travel to present study results. NEIE is an employee of the Center of Molecular Immunology, the research institution that patented and manufactures nimotuzumab. DR is an employee of Oncoscience GmbH. FB was an employee and has had stock options of Oncoscience GmbH that funded this study and has provided the investigational drug.
: All procedures performed in this study involving human participants were in accordance with the ethical standards of the institutional and national committees. The trial was conducted in accordance with 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The institutional review boards or ethics committees of all participating centers reviewed and approved the protocol. All parents/guardians and patients, where appropriate, gave their written informed consent.